Myeloma News and Research

RSS

FDA approves ibrutinib for treatment of mantle cell lymphoma

Today's U.S. Food and Drug Administration approval of ibrutinib to treat patients with mantle cell lymphoma is a significant advance for patients with this blood cancer. It was approved as a single agent for treatment of patients with MCL who have received at least one prior therapy.

14 Nov 2013

Patrys initiates IST of PAT-SM6 in combination with carfilzomib in multiple myeloma patients

Patrys Limited, a clinical stage biotechnology company has today announced that it is initiating an investigator-sponsored trial evaluating the effectiveness of Patrys’ lead anti-cancer drug PAT-SM6 in combination with carfilzomib, in patients with relapsed and refractory multiple myeloma.

11 Nov 2013

Patrys receives FDA Orphan Medicinal Product Designation for PAT-SM6

Patrys Limited, a clinical stage biotechnology company, has received confirmation of Orphan Medicinal Product Designation for its lead anti-cancer product PAT-SM6, from the USA Food and Drugs Administration.

7 Nov 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

Study evaluates sexual well-being in SCT survivors using sexual function assessment tools

New research ties preparative procedures and complications associated with blood or bone marrow transplantation (stem cell transplantation, SCT) with diminished sexual health in both men and women who have undergone the lifesaving procedure. Study data, published online today in Blood, the Journal of the American Society of Hematology, confirm chronic graft-versus-host disease, a serious complication that occurs when donor cells attack the recipient's cells, as a potential source of sexual dysfunction and are the first to demonstrate an association between total body irradiation and sexual dysfunction in men.

25 Oct 2013

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC).

21 Oct 2013

Promising new type of cancer treatment to benefit more patients

More patients than ever stand to benefit from a promising new type of cancer treatment, after scientists compiled a library of molecules that can prime patients’ immune systems to fight a range of cancers including leukaemia, myeloma, lung cancer and skin cancer.

15 Oct 2013

Research findings may lead to new ways to combat cancer

The way cells divide to form new cells - to support growth, to repair damaged tissues, or simply to maintain our healthy adult functioning - is controlled in previously unsuspected ways UC San Francisco researchers have discovered.

12 Oct 2013

Researchers discover why multiple myeloma recurs after initially effective treatment

Researchers have discovered why multiple myeloma, a difficult to cure cancer of the bone marrow, frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years.

19 Sep 2013

Binaytara Foundation, UIC partner to develop Nepal's first blood and marrow transplant unit

The University of Illinois at Chicago and the Binaytara Foundation have partnered to develop Nepal's first blood and marrow transplant unit and to organize the country's first international conference on blood cancers.

12 Sep 2013

Researchers discover why multiple myeloma persistently escapes cure

Clinical researchers at Princess Margaret Cancer Centre have discovered why multiple myeloma, an incurable cancer of the bone marrow, persistently escapes cure by an initially effective treatment that can keep the disease at bay for up to several years.

10 Sep 2013

$Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma$

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

The Lancet Oncology published this week findings from a study, which showed that the new oral therapy IMNOVID®▼ (pomalidomide), used in combination with low-dose dexamethasone demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM).1

5 Sep 2013

Viralytics releases financial results for 2013

Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013.

3 Sep 2013

LLS survey uncovers alarming lack of knowledge among U.S. adults about blood cancers

Less than one half (46%) of adults polled in a new survey believe that blood cancers are one of three leading causes of cancer death in the U.S. In fact, blood cancers are the third leading cause of cancer death, behind cancers of the respiratory system, including lung cancer, and cancers of the digestive system, including colorectal cancer.

30 Aug 2013

FDA approves NDA filing for ibrutinib inhibitor in two B-cell malignancies

Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

29 Aug 2013

Aging Gene Tied To Myeloma

...

22 Aug 2013

Oncopeptides launches phase II study to determine efficacy of melflufen in treatement of multiple myeloma

Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).

21 Aug 2013

Combination of anti-nausea drug and turmeric spice target cancer cells

In a laboratory, preclinical study recently published by the journal Organic & Biomolecular Chemistry, Virginia Commonwealth University Massey Cancer Center researchers combined structural features from anti-nausea drug thalidomide with common kitchen spice turmeric to create hybrid molecules that effectively kill multiple myeloma cells.

20 Aug 2013

Study: Gene that controls ageing process linked to cancer

A gene that helps control the ageing process by acting as a cell's internal clock has been linked to cancer by a major new study.

19 Aug 2013

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes.

13 Aug 2013